IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Docket No.: PF290P1D2

Ni et al.

Application No.: Not Yet Assigned Group Art Unit: N/A

Filed: Concurrently Herewith Examiner: Not Yet Assigned

For: Pancreas-Derived Plasminogen Activator

Inhibitor

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references A-BW listed on the attached Form SB/08.

Copies of references A-BW were submitted by Applicants or cited by the Examiner in connection with United States Patent Application No. 09/902,684, filed on July 12, 2001, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application No. 09/902,684 for copies of references A-BW.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Dated: July 29, 2003

Respectfully submitted,

Melissa J. Pytel
Registration No.: 41,512

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue Rockville, Maryland 20850

(301) 610-5764

KKH/MJP/ba

Docket No.: PF290P1D2

Under the Paperwork Reduction Act of 1995, no persons are required to respon

Sut	bstitute for form 1449/PTO			Complete if Known		
				Application Number	Not Yet Assigned	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	Concurrently Herewith	
S	TATEMENT B	BY /	APPLICANT	First Named Inventor	Jian Ni	
i				Art Unit	N/A	
	(use as many she	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	6	Attorney Docket Number	PF290P1D2	

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
	Α	US-4,923,807	08-05-1990	Webb et al.		
	В	US-5,470,970	11-28-1995	Sager et al.		
	С	US-5,804,376	09-08-1998	Braxton et al.		

		FOREI	GN PATENT DO	OCUMENTS	_	
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	D	WO-96/34957	11-07-1996			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date
Signature	Considered
O.g. a.B.O	Considered

Sut	ostitute for form 1449/PTO			Complete if Known		
				Application Number	Not Yet Assigned	
11	NFORMATION	N DI	SCLOSURE	Filing Date	Concurrently Herewith	
S	TATEMENT I	BY A	APPLICANT	First Named Inventor	Jian Ni	
				Art Unit	N/A	
	(use as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	6	Attorney Docket Number	PF290P1D2	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	E	Barton, G.J., "Protein sequence alignment and database scanning," in: Protein Structure Prediction, A Practical Approach, Sternberg, M.J.E., ed., IRL Press at Oxford University Press, Oxford, UK, pp. 31-63 (August 1996).	
	F	Carrell, R.W. et al., "The Serpins: Evolution and Adaptation in a Family of Protease Inhibitors," <i>Cold Spring Harbor Symp. Quant. Biol.</i> 52:527-535, Cold Spring Harbor Laboratory (1987).	
	G	Cronshagen, U. et al., "A novel protein expressed exclusively in pancreatic cells is proposed to be a serpin," Abstract No. 247, <i>Eur. J. Cell Bio.</i> 94:83, Nature Publishing Group (1993).	
	Н	Cunningham, B.C. and Wells, J.A., "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis," <i>Science</i> 244:1081-1085, American Association for the Advancement of Science (1989).	
		Fazioli, F. and Blasi, F., "Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?," <i>TiPS</i> 15:25-29, Elsevier Science (1994).	
	J	George, D.G. et al., "Current Methods in Sequence Comparison and Analysis," in: Macromolecular Sequencing and Synthesis, Selected Methods and Applications, D.H. Schlesinger, ed., Alan R. Liss, Inc. New York, NY, pp. 127-149 (1988).	
	K	Ginsburg, D. et al., "cDNA Cloning of Human Plasminogen Activator-Inhibitor from Endothelial Cells," <i>J. Clin. Invest.</i> 78:1673-1680, American Society for Clinical Investigation (1986).	
	L	Krishnamurti, C. et al., "Stimulation Of Plasminogen Activator Inhibitor Activity In Human Monocytes Infected With Dengue Virus," <i>Am. J. Trop. Med. Hyg.</i> 40:102-107, American Society of Tropical Medicine and Hygiene (1989).	
	М	Kruithof, E.K.O. et al., "Biological and Clinical Aspects of Plasminogen Activator Inhibitor Type 2," <i>Blood</i> 86:4007-4024, Journal of the American Society of Hematology (December 1995).	
	N	Leiper, K. et al., "Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease," <i>J. Clin. Pathol.</i> 47:214-217, BMJ Publishing Group (1994).	

Examiner	Date	
Signature	Considered	

Sub	Substitute for form 1449/PTO			Complete if Known		
				Application Number	Not Yet Assigned	
11	NFORMATIO	N DIS	SCLOSURE	Filing Date	Concurrently Herewith	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Jian Ni	
				Art Unit	N/A	
	(use as many sl	heets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	3	of	6	Attorney Docket Number	PF290P1D2	

C	Ngo, J.T. et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in: The Protein Folding Problem and Tertiary Structure Prediction, Mertz, Jr., K. and Le Grand, S., eds., Birkhauser,
	Boston, Massachusetts, pp. 491-495 (1994).
P	primary structure," in: Introduction to Proteins and Protein Engineering, Elsevier, Amsterdam, Holland pp. 41-43 (1986).
G	hormone sequence," in: Peptide Hormones, Parsons, J.A., eds., University Park Press, Baltimore, Maryland, pp. 5-7 (1976).
R	Characterization of Two Novel Members of the Ovalbumin Family of Serine Proteinase Inhibitors," <i>J. Biol. Chem.</i> 270:29854-29861, American Society for Biochemistry and Molecular Biology (December 1995).
S	the Murine Homologue of Human Proteinase Inhibitor 6 (PI-6) Suggests Divergence of PI-6 from the Ovalbumin Serpins," <i>J. Biol. Chem.</i> 270:16089-16096, American Society for Biochemistry and Molecular Biology (July 1995).
T	Urano, T. et al., "A substrate-like form of plasminogen-activator-inhibitor type 1," <i>Eur. J. Biochem.</i> 209:985-992, Federation of European Biochemical Societies (1992).
U	Wells, J.A., "Additivity of Mutational Effects in Proteins," <i>Biochem.</i> 29:8509-8516, American Chemical Society (1990).
V	Genbank Report, Accession No. Z30585, submitted by Cronshagen, U. et al. (1994).
W	(January 1995).
X	Genbank Report, Accession No. X16383, submitted by Sawdey, M.S. (February 1995).
Y	Genbank Report, Accession No. D13909, submitted by Mimuro et al. (November 1995).
Z	(February 1995).
AA	
AE	· • • • • • • • • • • • • • • • • • • •

Examiner	Date	
Signature	Considered	
		<u>1</u>

Sut	ostitute for form 1449/PTC)		Complet if Known		
				Application Number	Not Yet Assigned	
11	NFORMATIO	N DIS	CLOSURE	Filing Date	Concurrently Herewith	
S	TATEMENT	BY AF	PLICANT	First Named Inventor	Jian Ni	
				Art Unit	N/A	
	(use as many s	sheets as ne	cessary)	Examiner Name	Not Yet Assigned	
Sheet	4	of	6	Attorney Docket Number	PF290P1D2	

AC	NCBI Entrez, GenBank Report, Accession No. H81869, from Hillier, L. et al. (November 1995).
AD	NCBI Entrez, GenBank Report, Accession No. H82168, from Hillier, L. et al. (November 1995).
AE	al. (November 1995).
AF	NCBI Entrez, GenBank Report, Accession No. N34066, from Hillier, L. et al. (January 1996).
AG	(January 1996).
АН	(April 1996).
AI	NCBI Entrez, GenBank Report, Accession No. C18938, from Fujiwara, T. et al. (October 1996).
AJ	al. (October 1996).
AK	(October 1996).
AL	NCBI Entrez, GenBank Report, Accession No. AA104570, from Marra, M. et al. (October 1996).
AM	al. (December 1996).
AN	al. (December 1996).
AO	al. (December 1996).
AP	al. (February 1997).
AQ	al. (February 1997).
AR	al. (April 1997).
AS	et al. (April 1997).
AT	NCBI Entrez, GenBank Report, Accession No. AA296389, from Adams, M.D. et al. (April 1997).
AU	et al. (April 1997).
AV	NCBI Entrez, GenBank Report, Accession No. AA317566, from Adams, M.D. et al. (April 1997).

Examiner	Date	
Signature	I Considered	

Substitute for form 1449/PTO		Complet if Known			
				Application Number	Not Yet Assigned
INFORMATION DISCLOSURE				Filing Date	Concurrently Herewith
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Jian Ni
				Art Unit	N/A
(use as many sheets as necessary)		Examiner Name	Not Yet Assigned		
Sheet	5	of	6	Attorney Docket Number	PF290P1D2

TAVAL	NCDI Catara ConDonis Donat Accession No. AA070000 from Adams M.D.
	NCBI Entrez, GenBank Report, Accession No. AA372832, from Adams, M.D. et al. (April 1997).
AX	NCBI Entrez, GenBank Report, Accession No. AA409232, from Ko, M.S.H. et al. (May 1997).
AY	NCBI Entrez, GenBank Report, Accession No. AA045132, from Hillier, L. et al. (May 1997).
AZ	NCBI Entrez, GenBank Report, Accession No. AA473834, from Marra, M. et al. (June 1997).
ВА	NCBI Entrez, GenBank Report, Accession No. H09005, from Hillier, L. et al. (June 1997).
	NCBI Entrez, GenBank Report, Accession No. AA544064, from Marra, M. et al. (August 1997).
ВС	NCBI Entrez, GenBank Report, Accession No. AA146811, from Hillier, L. et al. (August 1997).
BD	NCBI Entrez, GenBank Report, Accession No. AA242969, from Hillier, L. et al. (August 1997).
	NCBI Entrez, GenBank Report, Accession No. AA562720, from Marra, M. et al. (August 1997).
BF	NCBI Entrez, GenBank Report, Accession No. AA542814, from NCI-CGAP (August 1997).
BG	NCBI Entrez, GenBank Report, Accession No. AA571334, from Marra, M. et al. (August 1997).
BH	NCBI Entrez, GenBank Report, Accession No. C31835, from Kohara, Y. et al. (September 1997).
BI	NCBI Entrez, GenBank Report, Accession No. AA589090, from Marra, M. et al. (September 1997).
	NCBI Entrez, GenBank Report, Accession No. H52450, from Hillier, L. et al. (September 1995).
	NCBI Entrez, GenBank Report, Accession No. AA596670, from Marra, M. et al. (September 1997).
BL	NCBI Entrez, GenBank Report, Accession No. C67391, from Kohara, Y. et al. (September 1997).
ВМ	NCBI Entrez, GenBank Report, Accession No. C71498, from Kohara, Y. et al. (September 1997).
BN	NCBI Entrez, GenBank Report, Accession No. AA645751, from Marra, M. et al. (October 1997).
ВО	NCBI Entrez, GenBank Report, Accession No. AA666768, from Marra, M. et al. (November 1997).
	iai. (November 1001).

Examiner	Date	\neg
Signature	Considered	

Substitute for form 1449/PTO				Complete if Known		
				Application Number	Not Yet Assigned	
INFORMATION DISCLOSURE			SCLOSURE	Filing Date	Concurrently Herewith	
STATEMENT BY APPLICANT		First Named Inventor	Jian Ni			
				Art Unit	N/A	
(use as many sheets as necessary)		Examiner Name	Not Yet Assigned			
Sheet	6	of	6	Attorney Docket Number	PF290P1D2	

ВР	NCBI Entrez, GenBank Report, Accession No. AA684304, from Marra, M. et al. (December 1997).
BQ	NCBI Entrez, GenBank Report, Accession No. AA706757, from Hillier, L. et al. (December 1997).
BR	NCBI Entrez, GenBank Report, Accession No. AA738996, from Marra, M. et al. (1998).
BS	NCBI Entrez, GenBank Report, Accession No. AA487997, from Hillier, L. et al. (1998).
ВТ	NCBI Entrez, GenBank Report, Accession No. AA852339, from Jia, L. et al. (1998).
BU	NCBI Entrez, GenBank Report, Accession No. AA867587, from Marra, M. et al. (1998).
BV	NCBI Entrez, GenBank Report, Accession No. AA869929, from Marra, M. et al. (1998).
BW	NCBI Entrez, GenBank Report, Accession No. AA869413, from Marra, M. et al. (1998).

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	
0.3	 Jonaldered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.